Propanc Biopharma, Inc.
No SEC Form 4 filings for $PPCB in the last 30 days.
See all $PPCB insider activity →Propanc Biopharma (PPCB) reported positive preclinical data for PRP in pancreatic cancer, showing over 90% tumor growth inhibition and extended survival in models. The treatment also improved chemo-resistance and tumor environment. PPCB stock surged 249.59% to $3.69 on Nasdaq. The company plans a Phase 1b study with a clinical trial application expected soon.
Propanc Biopharma, Inc. (PPCB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 INDEPENDENT DIRECTOR AGREEMENT THIS INDEPENDENT DIRECTOR AGREEMENT (this “ Agreement ”), is made effective as of July 8, 2026, and is by and between Propanc Biopharma, Inc., a Delaware corporation (the “ Company ”), and the undersigned (t
Propanc Biopharma (PPCB) said it signed an MOU with Avance Clinical Pty Ltd to collaborate on clinical delivery of its planned Phase 1b first-in-human trial of PRP for advanced solid tumors. The study will assess safety, tolerability, pharmacokinetics, immunogenicity, and preliminary activity. PPCB also noted a 1-for-25 reverse split on May 18, 2026.
Over the past 7 days, alphai's AI scored 2 news stories mentioning PPCB (Propanc Biopharma, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent PPCB coverage spans financial news, technology and corporate actions.
Positive preclinical results could boost investor optimism and support a higher valuation ahead of Phase 1b filing.
Board composition and director compensation details are unlikely to change near-term fundamentals, but they can affect governance optics and committee structure.
The MOU is a clinical execution milestone that can improve perceived readiness for Phase 1b, but it is not a binding contract or trial result.
The MOU is a step toward initiating PRP’s Phase 1b FIH study, potentially improving execution confidence but without trial results or firm start dates.
The buyback authorization is a concrete capital-return catalyst that can support sentiment and near-term trading.
alphai scores every news story that mentions PPCB with an AI model for sentiment and relevance, and aggregates insider trades from Propanc Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Propanc Biopharma (PPCB) reported positive preclinical data for PRP in pancreatic cancer, showing over 90% tumor growth inhibition and extended survival in models. The treatment also improved chemo-resistance and tumor environment. PPCB stock surged 249.59% to $3.69 on Nasdaq. The company plans a Phase 1b study with a clinical trial application expected soon.
2 min readPropanc Biopharma, Inc. (PPCB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 INDEPENDENT DIRECTOR AGREEMENT THIS INDEPENDENT DIRECTOR AGREEMENT (this “ Agreement ”), is made effective as of July 8, 2026, and is by and between Propanc Biopharma, Inc., a Delaware corporation (the “ Company ”), and the undersigned (t
2 min readPropanc Biopharma (PPCB) said it signed an MOU with Avance Clinical Pty Ltd to collaborate on clinical delivery of its planned Phase 1b first-in-human trial of PRP for advanced solid tumors. The study will assess safety, tolerability, pharmacokinetics, immunogenicity, and preliminary activity. PPCB also noted a 1-for-25 reverse split on May 18, 2026.
4 min readPropanc Biopharma (Nasdaq: PPCB) said it signed an MOU with Avance Clinical Pty Ltd to support delivery of Propanc’s Phase 1b first-in-human trial of PRP in advanced solid tumors. The CRO will help with trial design and execution, aiming to generate data to move PRP toward proof-of-concept and later phases.
3 min readBiotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG
7 min readPropanc Biopharma, Inc. (PPCB) shares rose about 26% after the company said it started a share repurchase program to buy a first tranche of up to $500,000 over 30 days. The stock was around $1.8150 on Nasdaq, up about 25.7% in the latest session.
2 min readPropanc Biopharma, Inc. (Nasdaq: PPCB) said it has started a share repurchase program authorizing a first tranche of up to $500,000 to buy back common stock over the next 30 days. Purchases may occur under Rule 10b5-1 and other methods, and the company may modify, suspend, or end the program at any time.
3 min readPropanc Biopharma (PPCB) said its board approved a share repurchase program authorizing buybacks of up to $5.0 million of its common stock. The company expects the program to support shareholder ownership and improve per-share economics, citing management’s capital allocation approach. In pre-market trading, PPCB was at $2.87, up 114.23% on Nasdaq.
2 min readShareStructure.io launched a free investor education and research platform on public-company financing activity, SEC filings, capital structures, dilution risks, and shareholder-related disclosures. The platform offers a 10-module course plus watchlists and filing analysis tools. It also highlights EDHL, PPCB, and GLXG financing structures, including EDHL’s 7M selling shares and PPCB’s 85% conversion terms.
4 min read
